Valeant Pharmaceuticals is preparing to officially launch its long-promised hostile takeover bid for Allergan (NYSE:AGN), aiming to solicit support from Allergan shareholders to host a special meeting outside of the company’s control.
Mergers & Acquisitions
Op-ed: Medtronic/Covidien deal good for patients, Minnesota
By: Shaye Mandle, President & CEO, LifeScience Alley
LifeScience Alley, the nation’s largest regional life science industry association, welcomes the news that Medtronic, the world’s leading provider of medical technology products, services and solutions, is acquiring Covidien, a leading global healthcare technology and medical supplies provider.
Medtronic buyout holds $80M in golden parachutes for Covidien execs
If the top executives at Covidien decide to leave the company after a $43 billion acquisition by Medtronic goes through, they’ll do it under a golden parachute worth a collective $80 million, regulatory filings show.
Medtronic’s OUS move becomes a political football | MassDevice.com On Call
Hill-Rom to pay $250M for German OR infrastructure maker
Hill-Rom Holdings (NYSE:HRC) said today that it agreed to put up $250 million in cash for the operating room infrastructure arm of Germany’s Trumpf Group.
Analysis: What does the union of Medtronic and Covidien mean for medtech?
By Brad Perriello and Brian Johnson
UPDATED June 16, 2014, with additional comment from Leerink Partners analyst Danielle Antalffy.
Blockbuster: Medtronic in $43B deal to acquire Covidien
Ackman takes Allergan to court to defend against ‘poison pill’
Stentys closes $1.4M acquisition of Cappella’s Peel Away stent delivery device
Stentys said it’s closed the deal on the €1 million ($1.4 million) deal to acquire the Peel Away stent delivery system.
The cash-and-stock deal is the 1st strategic acquisition for Stentys, which makes a line of bare-metal and drug-eluting coronary stents.